Survodutide Shows 16.6% Weight Loss in Phase 3 Trial, Could Rival Zepbound for Obesity and Liver Disease Treatment

Boehringer Ingelheim has announced promising results from its Phase 3 SYNCHRONIZE-1 clinical trial of survodutide, a next-generation GLP-1 drug designed to treat obesity and related metabolic conditions. The trial, which concluded in April 2026 after 76 weeks of treatment, involved 725 adults living with obesity or overweight but without type 2 diabetes across multiple international sites.

The drug, which activates both glucagon-like peptide-1 (GLP-1) and glucagon receptors, demonstrated significant and sustained weight loss. Participants lost an average of 16.6% of their body weight, a substantial improvement compared to just 3.2% in the placebo group.

In addition to weight loss, survodutide showed meaningful metabolic improvements, including reductions in waist circumference—a key predictor of cardiometabolic risk. These findings suggest the drug’s potential to address obesity-related diseases such as liver dysfunction and metabolic dysfunction-associated steatohepatitis (MASH).

How Survodutide Compares to Existing GLP-1 Drugs Like Zepbound

Survodutide (BI 456906) shares similarities with tirzepatide, the active ingredient in Mounjaro and Zepbound, in that it combines two mechanisms of action. However, it targets a different combination of hormone receptors. While GLP-1 receptor agonists like Zepbound reduce appetite and increase fullness, survodutide goes further by also activating glucagon receptors, which may help regulate metabolic functions in the liver.

This dual-action approach could provide an additional reduction in liver fat, potentially helping to reduce liver inflammation and fibrosis—two major causes of obesity-related complications.

Key Findings from the SYNCHRONIZE-1 Trial

The trial evaluated survodutide’s safety and efficacy in adults with overweight or obesity, excluding those with type 2 diabetes. Participants received weekly injections of survodutide at doses of 3.6 mg or 6.0 mg, or a placebo, over nearly a year and a half.

The primary goals of the study were to assess the percentage change in body weight and the proportion of participants achieving at least a 5% reduction in body weight from baseline after 76 weeks of treatment. The results were striking:

• Up to 85.1% of those treated with survodutide achieved at least a 5% reduction in their weight, compared to only 38.8% in the placebo group.
• On average, participants lost 16.6% of their body weight, equivalent to about 39.2 pounds.
• The weight loss was primarily composed of fat rather than lean muscle tissue.
• There was a significant decrease in waist circumference among participants, a marker linked to visceral abdominal fat and metabolic dysfunction.

Is Survodutide Safe and Effective for Weight Loss?

While the results are promising, survodutide is not yet approved for use. The drug’s safety and efficacy will need to be further evaluated by regulatory agencies before it can be made available to patients. However, the Phase 3 trial results suggest that survodutide could offer a significant advancement in the treatment of obesity and related metabolic diseases.

Experts believe that the dual-action mechanism of survodutide—targeting both GLP-1 and glucagon receptors—could provide a more comprehensive approach to improving metabolic health compared to existing GLP-1 drugs. If approved, it may become a strong competitor to therapies like Zepbound in the growing market for obesity and metabolic disorder treatments.